Abstract
Persistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed multiple myeloma (MM). The use of stem cell boosts in ICAHT has been described, however studies have been limited by small patient numbers and short follow up. Herein, we report on our multi-institutional experience of ICAHT, defined by an absolute neutrophil count (ANC) of ≤ 1000, thrombocytopenia with a platelet count ≤ 50,000 or/and anemia as hemoglobin (hgb) ≤9 g/dL, in patients who received BCMA CAR T therapy, and the effects of subsequent stem cell boost on hematopoietic reconstitution and clinical outcome. In this study, ICAHT was observed in 60% (n = 61/101) of patients at D + 21, and risk factors for its development included history of a prior ASCT, higher number of prior lines of therapy, a decreased platelet count prior to lymphodepletion and history of ICANS. 28% of patients with ICAHT received a stem cell boost at a median of 116 days due to profound and prolonged cytopenias often requiring ongoing transfusion support. Stem cell boost significantly improved cytopenias at 3 and 6 months follow up without any adverse effects on PFS and OS, underscoring the safety of this procedure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Data will be provided upon reasonable to the corresponding author.
References
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, et al. Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations. Blood 2023. https://doi.org/10.1182/blood.2023020578.
Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850.
Raje NS, Siegel DS, Jagannath S, Lonial S, Munshi NC, Moreau P, et al. Idecabtagene Vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study. Blood. 2020;136:37–38. https://doi.org/10.1182/blood-2020-134319.
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://doi.org/10.1016/S0140-6736(21)00933-8.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335–47. https://doi.org/10.1056/NEJMoa2303379.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2213614.
Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. https://doi.org/10.1056/NEJMoa2203478.
Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodríguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232–44. https://doi.org/10.1056/NEJMoa2204591.
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023. https://doi.org/10.1038/s41591-023-02528-9.
Gagelmann N, Wulf GG, Duell J, Glass B, van Heteren P, von Tresckow B, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. Blood Adv. 2023;7:555–9. https://doi.org/10.1182/bloodadvances.2022008042.
Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460–9. https://doi.org/10.1182/blood.2022017415.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transpl. 2020;26:26–33. https://doi.org/10.1016/j.bbmt.2019.08.003.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138:2499–513. https://doi.org/10.1182/blood.2020010543.
Nahas GR, Komanduri KV, Pereira D, Goodman M, Jimenez AM, Beitinjaneh A, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61:940–3. https://doi.org/10.1080/10428194.2019.1697814.
Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54:1643–50. https://doi.org/10.1038/s41409-019-0487-3.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776–87. https://doi.org/10.1182/bloodadvances.2020002509.
Kitamura W, Asada N, Naoi Y, Abe M, Fujiwara H, Ennishi D, et al. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. Br J Haematol. 2023;202:294–307. https://doi.org/10.1111/bjh.18747.
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664–79. https://doi.org/10.1158/2159-8290.cd-16-0040.
Xingmin F, Phillip S, Colin OW, Leigh S, Olga N, Courtney P, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2011;96:602–6. https://doi.org/10.3324/haematol.2010.030536.
Miller KC, Johnson PC, Abramson JS, Soumerai JD, Yee AJ, Branagan AR, et al. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022;12:146 https://doi.org/10.1038/s41408-022-00741-2.
Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022;6:6109–19. https://doi.org/10.1182/bloodadvances.2022008320.
Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed car T-cell therapy. Transpl Cell Ther. 2023;29:567–71. https://doi.org/10.1016/j.jtct.2023.05.012.
Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, et al. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103:1047–53. https://doi.org/10.3324/haematol.2017.177139.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT lls. Biol Blood Marrow Transplant. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758.
Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023;16:88 https://doi.org/10.1186/s13045-023-01465-x.
Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23:943–7. https://doi.org/10.1634/theoncologist.2018-0028.
Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720–5. https://doi.org/10.1182/blood.V98.9.2720.
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850.
Sidana S, Hosoya H, Jensen A, Liu L, Goyal A, Hovanky V. et al. Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer J. 2023;13:158 https://doi.org/10.1038/s41408-023-00929-0.
Acknowledgements
Advancing a Healthier Wisconsin Endowment-CTSI KL2 award (M.M). List of where and when the study has been presented in part elsewhere, if applicable: This work will be partly presented as an oral abstract at the 65th American Society of Hematology Annual Meeting and Exposition, Dec 9–12, 2023, San Diego, California.
Author information
Authors and Affiliations
Contributions
Conception and design: MM MD, MS; CS MD. Provision of study materials or patients: MM MD, MS; JE RN; CS PA; AG APRN; SAH MD MS; SVR MD; ST MD; MZ MD; NS MD; FvR MD Ph.D.; BD MD, MS; MH MD; AD’S MD, MS; CS MD. Collection and assembly of data: MM MD, MS; JE RN; TPq, MD; RB MD; AJ BA; VB MD; EA BS; CS MD. Data analysis and interpretation: AS Ph. D, LER Sc, MM MD, MS; CS MD. Manuscript writing: MM MD, MS; CS MD. Final approval of manuscript: All author. Non-Author Contributions to Data Collection, Analysis, Or Writing/Editing Assistance: Not Applicable.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mohan, M., Szabo, A., Patwari, A. et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant 59, 647–652 (2024). https://doi.org/10.1038/s41409-024-02233-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-024-02233-2